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ABSTRACT 
In recent years, most of the research on the control of sylvatic rabies has concentrated on 
developing methods of oral vaccination of wild rabies vectors. In order to improve both the safety 
and the stability of the vaccine used, a recombinant vaccinia virus, which expresses the 
immunizing glycoprotein of rabies virus (VRG), has been developed and extensively tested in the 
laboratory as well as in the field. Between 1989 and 1995, several million VRG vaccine doses have 
been dispersed in Western Europe for the vaccination of red foxes, leading to the elimination of 
sylvatic rabies from large areas, which have consequently been freed from the need for 
vaccination. This approach ma)’ have consequences for the regulation of pet movement within the 
whole European Union. 
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INTRODUCTION 
The present Western European terrestrial epizootic of rabies has spread some 1400km westwards 
from Poland since 1939. For several years, the front of the epizootic advanced 20-60km per year 
(Toma & Andral, 1977; MacDonald, 1988). This terrestrial epizootic is sylvatic: the reservoir of 
infection is in wildlife. While all susceptible species, both wild and domestic can develop rabies, the 
red fox (Vulpes vulpes) is involved in more than 75% of cases and is both the vector of the disease 
and its reservoir. Although the red fox plays a key role in the maintenance of the disease, it does 
not usually transmit it directly to humans which are mainly at risk from affected domestic animals 
such as cattle (Pastoret et al., 1995). The dog is, however, a rare excretor of the vulpine strain of 
rabies. 
The percentage of rabid foxes is underestimated for several reasons. In fact, the proportion of 
rabies cases reported is likely to be as low as 2-10%; this can cause problems in detecting 
outbreaks (Bacon, 1981) and, conversely, the impact of the epizootic on wildlife is therefore 
important (King & Turner, 1993). For example, the occurrence of the disease in cubs in the den is 
always neglected, but could be frequent (Thiriart et al., 1985). The fox seems to be the only species 
maintaining the present terrestrial epizootic; if rabies were to be eliminated from the fox 
population it would cease to be a problem in other wildlife or domestic species. In Western Europe, 
rabies is considered a source of economic loss and, above all, hampers the movement of animals 
between the different member states of the European Union (EU). This has serious implications for 
the ‘open market’ since some member states are currently rabies free and wish to maintain their 
disease-free status. Therefore, the control of rabies requires a common strategy to be established 
at EU level. 
In 1986, several infected EU countries decided to tackle this task together (Pastoret et al., 1987; 
Brochier et al., 1988) by vaccinating foxes orally against rabies. This programme was supported by 
the European Gommission from the beginning and has led to the near extinction of fox rabies in 
Western Europe. Thus, the situation is rapidly evolving in the field, and it is timely to consider 
modifying EU rabies regulations. 
HISTORY OF URBAN RABIES IN GREAT BRITAIN 
Rabies may be maintained in two not necessarily interrelated cycles, urban and sylvalic. Urban 
rabies, affecting stray and feral dogs and cats, is by far the more dangerous to humans, accounting 
for an estimated 99% of all recorded human cases and for 92% of all human post-exposure 
treatments (Pastoret et al., 1995). Sylvalic rabies is characterized by the involvement of one or two 
main species in particular locations and this pattern remains stable over many years (Chalmers & 
Scott, 1969). In continental Europe, sylvalic rabies has been reported since the Middle Ages but has 
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been intensively studied only since the current upsurge began at the beginning of World War II 
(King & Turner, 1993) when urban rabies had virtually disappeared. 
Rabies was a common disease in Cheat Britain for many centuries (Fleming, 1872; King & Turner, 
1993). The first allusion to the disease seems to have been in 1026 in the laws of Howell the Good of 
Wales (cited by Fleming, 1871). The prevalence of the disease increased from 1735, and by 1776 
rabies was widespread in dogs throughout Britain. Mad dogs were reported in London from 1752 to 
1862. Despite a significant fox population, the disease was not observed in wildlife except for two 
outbreaks in deer at Barnsley in 1856 when 100 animals were affected, and in Richmond Park, 
London, in 1886, when 257 fallow deer (Cennts dama) died but did not pass on the disease to red 
deer (Omits elafihus) in the same park. 
Between 1889 and 1898, over 160 human cases of rabies were recorded in Britain. From 1897 
onwards, the implementation of Orders, which included powers for the muzzling of dogs, the elim-
ination of stray dogs, the tracing of movement of rabid dogs and their contacts, and the regulation 
and control of the importation of dogs, led to the eradication of the disease for the first time in 
1902. Rabies was reintroduced in 1918 and 328 further animal cases were found in the south of 
England before the disease was finally eradicated in 1922. However, since then, a further 21 
recorded human deaths have resulted from infection acquired abroad. Except for two dogs, which 
became rabid after release from quarantine, import regulations, including quarantine of imported 
dogs and cats, have kept Britain free of animal rabies since 1922. 
During the 49 year period 1922-1970, 29 animals have died of rabies in quarantine. However, in the 
21 year period (1971-1991) since the immunization of cats and dogs with inactivated vaccines of 
cell culture origin within quarantine was introduced, only two dogs have died in quarantine with 
evidence of rabies in the brain. Since 1971, of nearly 200000 imported cals and dogs immunized 
within quarantine, none has died of rabies after release. It should also be noted that among all the 
cases of rabies in animals imported into Britain, none was due to a previous contamination with 
fox rabies in another country belonging to the EU. In fact, urban rabies disappeared from other 
western European countries during the same period. 
BIOLOGY OF RABIES VIRUS INFECTION IN FOXES 
The present epizootic of fox rabies in Western Europe seems to have started at the Russian-Polish 
border, and the prevailing hypothesis is that the virus originated in dogs and became adapted, 
through successive stages, for foxes (Winkler, 1975). The virus strain is highlv pathogenic for the 
fox: a dose of 0.3 mouse intracerebral LD30 is sufficient to kill one fox in Iwo, whereas domestic 
carnivores require a dose 1000000 times greater to produce the same effect (Blancou et al., 1991a). 
As the rabies front penetrates a new area, the foxes within the area suf fer an epizootic of the 
disease and when the fox population has been severelv reduced, the incidence of the disease 
decreases and remains low for a ‘silent’ period of some 2-3 years. After the initial epizootic, 
secondary enzootic outbreaks recur, often at intervals of 3-5 years (Macdonald & Voigt, 1985). 
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Superimposed upon the annual variance in the incidence of reported cases of vulpine rabies is a 
seasonal pattern. Cases tend to peak in late winter and reach a trough in midsummer. The late 
winler/early spring peak seems to be linked to the mating season of foxes. In recent years, the 
advance of the rabies epizootic, which had previously progressed 20-60km year in Europe, seems 
to have stopped, possibly due to strain variations or to the ecology' of transmission. 
In Europe, the fox is certainly the animal species most susceptible to vidpine rabies infection, and 
the proportion of rabid foxes that excrete the virus is very high: 93-100% of rabid foxes harbours 
the virus in the salivary glands and excrete it in large amounts in saliva. Furthermore, the virus can 
be excreted for up to 29 days before the onset of the disease (Aubert et al., 1991). 
The incubation period of the disease in foxes depends mainly on the dose of virus with which the 
animal has been infected and varies from 10-41 days. The clinical disease, which is transmitted by 
biting, lasts 3-5 days. The signs are variable (George et al., 1980), The furious form is relatively rare 
and most animals become apathetic and develop paralysis. Since the apathetic form of the disease 
predominates in the fox, rabid foxes do not usually wander far from their original territory (Artois & 
Aubert, 1985). This may explain why the front of a fox rabies epizootic progresses slowly. 
CONTROL OF FOX RABIES 
Prophylactic measures taken in the past, such as the destruction of foxes to reduce the population, 
did not prevent the spread of the epizootic. During recent years, most of the research on the 
control of fox rabies has concentrated on the development of methods of oral vaccination of the 
fox (Steck et al., 1982) which has been extensively used in all infected countries of the EU. The 
research has focused on oral vaccination because it is the only means of immunizing a sufficient 
proportion (75%) of wild foxes, through the distribution of vaccine baits; as such, the only vaccines 
that could be used were either attenuated strains of rabies virus or live, vectored vaccines. 
Inactivated rabies vaccines are useless when given orally (Brochier et al., 1985). 
In 1986, in order to develop a common strategy for the EU, a coordinated trial of oral vaccination of 
foxes was undertaken in several European countries using the SAD B19 attenuated strain of rabies 
in order to assess both the efficacy and the feasibility of the method (Pastoret et al., 1987). The 
results of these campaigns confirmed the efficacy of fox vaccination for the control of sylvatic 
rabies. 
The use of attenuated rabies virus, however, remains controversial as far as safety and stability are 
concerned, as these virus strains are still pathogenic for laboratory, and wild rodents, as well as for 
wildlife species, such as the chacma baboon (Papio ursiniis) and target species such as the striped 
skunk (Mephitis mephitis) (Pastoret et al., 1994); moreover, these strains may still be pathogenic to 
man. Humans exposed to SAD-derived attenuated strains of rabies must be treated with a 
conventional inactivated rabies vaccine which elicits good cross-protective immunity. The SAD-
derived attenuated strain may also be inefficient for some rabies vectors such as the racoon 
(Procyon lolor) in North America. 
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The pathogenicity of attenuated rabies virus strains can be abolished by mutating arginine resi-
dues at position 333 of the rabies virus glycoprotein (Tuffereau et al., 1989). This has led to the 
development of a new attenuated vaccine strain already used in the field (Kihm et al., 1992). 
Nevertheless, another inconvenience of attenuated strains of rabies virus is their heat sensitivity 
(Pastoret et al., 1996) which reduces their potential efficacy in field conditions. In order to improve 
both the safety and stability of the vaccines used for fox vaccination in the field, a recombinant 
vaccinia virus which expresses the immunizing glycoprotein of rabies virus (VRG) has been 
developed and tested in the field for oral vaccination of foxes (Kieny et al., 1984; Blancou et al., 
1986; Brochier et al., 1990; Pastoret et al., 1992). 
DEVELOPMENT AND DELIBERATE RELEASE OF A VACCINIA-
RABIES GLYCOPROTEIN RECOMBINANT VIRUS (VRG) FOR 
ORAL VACCINATION OF FOXES AGAINST RABIES 
The recombinant vaccinia-rabies glycoprotein virus (VRG) has been tested for efficacy and safety in 
the fox (Blancou et al., 1986; Boulanger et al., 1995). The duration of protection conferred by VRG, a 
minimum of 12 months in cubs and 18 months in adult animals, corresponds to the length of 
protection required for fox vaccination in the field, due to the high turnover of the population. The 
efficacy of VRG contained in a machine-made baiting system has been tested (Brochier et al., 
1990a) and shown to be effective. 
VRG was shown to be non-pathogenic in the fox (Pastoret et al., 1992; Boulanger et al., 1995) what-
ever the inoculation dose or route of administration. No transmission of immunizing amounts of 
VRG was found to occur in adult or young foxes, with the exception of one adult fox bitten by 
another fox which had been fully vaccinated. VRG only multiplies locally (Thomas et al., 1990). 
The influence of vaccination with VRG on the onset of the disease and on the delay before death in 
foxes previously infected with wild rabies virus has been investigated. The results show that ‘early’ 
and ‘late’ death phenomena occur as a consequence of interactions between oral vaccination with 
VRG and rabies infection, but preclude the risk of the emergence of asymptomatic carriers of wild-
rabies virus after vaccination (Brochier et al., 1989a). Field trials with baits have shown that several 
non-target wildlife species compete with foxes for bait consumption. It must also be recognized 
that, within the orthopoxvirus group, vaccinia virus has a wide range of host species. In fact, bait-
uptake monitoring and tetracycline (included as a biomarker within the bait) detection controls, 
performed after vaccination campaigns, proved that mustelids, wild boars (Sus scrofa) and 
domestic carnivores may ingest the vaccine bait and a significant proportion of the baits are partly 
eaten by small mammals. It was therefore important to verify the safety of VRG for non-target 
species (both domestic and wild). 
Several non-target wild species were chosen for testing in Europe because of their opportunistic 
feeding behaviour and their presence in the areas where the vaccine is to be distributed (Brochier 
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et al., 1989b, 1996); these include wild boar, the Eurasian badger (Meles meles) and several 
micromammals. No clinical signs of rabies and/or pox-inflicted lesions were observed in the 
vaccinated animals during the observation period (28 days minimum after vaccination). Similar 
experiments were undertaken in the United States of America in other target species (Hanlon et al., 
1997); serological surveys of orthopoxvirus circulation in wild mammals were also done, showing 
that the risk of recombination between the recombinant vaccinia-rabies virus and a wild 
orthopoxvirus such as cow-pox were nearly nil (Boulanger et al., 1996). 
Taking into account all the available experimental data concerning the safety of the VRG for target 
and non-target species and its efficacy in foxes, limited field trials of fox vaccination with the 
recombinant virus were authorized first by the Belgian (Pastoret et al., 1988; Brochier et al., 1991) 
and then by the French public health authorities. Similar trials were also undertaken later on in the 
United States of America (Brochier et al., 1996; Hanlon et al., 1998). 
TOWARDS ELIMINATION OF RABIES WITHIN THE EUROPEAN 
UNION 
The last trial of deliberate release of the VRG on a 2200km2 area of Southern Belgium was intended 
to test the feasibility of rabies eradication over a large area (Brochier et al., 1991). The 25 000 bails 
containing VRG and a tetracycline biomarker were dropped by helicopter on three occasions 
(November 1989, April 1990 and October 1990). After the third phase of vaccination, 81% (64/79) of 
inspected foxes were tetracycline positive. Only one rabid fox was recorded, at the periphery of the 
baited area, and this was tetracycline negative. Despite the dramatic decrease in the number of 
rabid foxes recorded after vaccine-bait distribution, the efficacy of the vaccination campaign 
remains difficult to evaluate because systematic collection of foxes is not logistically feasible. 
Nevertheless, because notification of cases of rabies in cattle and sheep is mandatory in Belgium, 
the incidence of rabies in livestock provides a reliable indicator of the prevalence of rabies in the 
wild. No case of livestock rabies has been recorded in the study zone since the second phase of 
vaccination. On this occasion. we investigated also the economics of the vaccine-baits dispersal 
programme. The average yearly cost of rabies in Belgium (1980-1989), including post-exposure 
treatments of humans, animal diagnosis, compensation to farmers for the culling of infected 
livestock, and the culling of wild foxes, was estimated to be 400000 ECUs per 10000 km-, or 88000 
ECUs per year for the area under study. These figures did not include the cost of vaccination of 
domestic animals nor the salaries of civil servants. In comparison we estimate the overall 
expenditure during the three campaigns of vaccine-bait distribution to be 118000 ECUs. Because 
vaccination following elimination can, in principle, be interrupted or subsequently limited to the 
borders of the vaccinated zone, long-term maintenance of a rabies-free area by peripheral 
vaccination with VRG is economically justifiable. The use of VRG has now been extended to all the 
contaminated areas in Belgium and to the Grand Duchy of Luxemburg as well as to large areas in 
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France. Rabies is now close to being eliminated from these three countries (Brochier et al., 1996, 
1997). 
The elimination of rabies in Belgium has already had other beneficial effects, besides the improve-
ment of animal health. First, the number of human post-exposure treatments has decreased in 
proportion to the decrease of rabies incidence in animals (mainly cattle). Second, the diminution 
of rabies incidence in wildlife has had a beneficial effect on the survival of threatened wild species, 
such as the Eurasian badger in the contaminated area, and estimates of the badger population in 
the treated area are now showing a gradual increase. 
VACCINATION OF PETS AGAINST RABIES 
Although between 1884 and 1885, Pasteur demonstrated the possibility of vaccinating dogs, it was 
only in the 1920s that domestic animal vaccination was developed and used in practice. The first 
vaccine widely used was the Semple type (Umeno & Doi, 1921). Later on, attenuated live virus and 
inactivated virus vaccines were developed. The adaptation of the fixed Flury strain to chicken 
embryos (Koprowski & Cox, 1948; Koprowski, 1954) led to the selection of two strains differing in 
the number of passages. Other strains, such as the ERA (Abelseth, 1964a, b), SAD, Kelevetc., have 
also been developed. Although only preventive vaccination of animals (before their exposure to 
the rabies virus) is authorized, in some instances post-exposure vaccination is possible, and 
curative treatments have been tested in several species. 
Rabies virus can be inactivated by physical agents (heat or ultraviolet rays) or chemical agents 
(phenol, ether, formalin, B-propiolactone, tri-N-butyl phosphate, ethyleneamine, or carbolic acid) 
or combinations of the two. Many cell-culture vaccines have been produced on either primary cells 
or cell lines (Soulebot et al., 1978; Precausta and Soulebot, 1991; Pastoret et al., 1993, 1997). 
One other route to produce vaccines involves the elaboration of antigenic material based upon 
non-replicating viral vectors expressing G protein, purified Ci protein, subfragments of G, or anti-
idiotypic antibodies raised against G (Prehaud et al., 1989). Other possibilities involve the use of 
new adjuvants (Morein et al., 1984; Osterhaus et al., 1986) or the addition of other rabies virus 
components, such as the N protein. The most promising new development comes, however, from 
abortively replicating avipoxvirus vectors. The natural productive host range of avipox viruses is 
limited to avian species. Nonetheless, abortive infection can be initiated in vitro in cell lines 
derived from non-avian species. Using avipox virus recombinants, foreign antigens can be 
authentically synthesized, processed and presented on the infected cell surface without infectious 
progeny virus being produced. Fowlpox and canarypox rabies recombinant viruses have been 
developed in which the gene coding for the rabies virus glycoprotein is expressed under the control 
of vaccinia virus promoters (Taylor et al., 1988,1991). 
Preventive vaccination being the rule in veterinary medicine, post-exposure vaccination can be 
allowed only if the animal, such as the dog, has been previously vaccinated before exposure. In 
such cases, failure to protect the animal has been reported in very few instances (1/3000). Some 
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experiments have been conducted in dogs, cats and sheep to check whether post-exposure 
treatment of these species was feasible and efficient. In sheep, it was shown that post-exposure 
treatment with rabies immunoglobulin and tissue culture vaccines protected all animals, but some 
animals which were treated only with vaccine died of rabies (Blancou et al., 1991b). 
PRESENT RABIES CONTROL MEASURES IN THE UNITED 
KINGDOM 
For most of this century, rabies control measures in Britain have relied on 6 months quarantine in 
approved premises for all mammals, except farm-stock and horses which are subject to other 
controls. All animals entering quarantine have been required to be vaccinated with an approved, 
inactivated rabies vaccine, and dogs also had to be vaccinated against distemper. Vaccination 
other than in quarantine or for export has not been allowed in the UK. In recent years, however, 
commercially traded dogs from EU States no longer had to undergo quarantine, but must come 
from approved premises, be vaccinated, test positive for antibody and be permanently identified 
with a microchip transponder (Pastoret et al., 1998). 
TOWARDS NEW EUROPEAN REGULATIONS 
As mentioned in the introductory section of this paper, rabies in Western Europe is considered a 
source of public health concern, economic loss and hampers the movement of animals between 
the different member states of the EU. Some member states, such as the UK, Spain and Portugal, 
are currently rabies free and wish to maintain their disease-free status. Therefore, the control of 
rabies requires a common strategy established at EU level. This has already begun since the 
European Commission pays for half of the fox rabies elimination programme cost and the 
programmes are discussed between the different countries concerned before implementation. 
Within the EU, a country will be declared rabies free after 2 years of epidemio-surveillance without 
any reported case of rabies in either wildlife or domestic animals. If previously infected member 
states become rabies free, it seems appropriate to consider the possibility of changing the rules 
governing animal traffic within the EU. The case for quarantine containment in the UK for pets 
coming from other rabies-free areas of the Union is particularly hard to justify bearing in mind that 
fox rabies has not been introduced into Spain by pets, travelling freely from contaminated 
countries; moreover, of the rabies cases in UK quarantine kennels, none originated from another 
member state of the EU. The risk of introducing fox rabies into the UK through pets from other 
member states is practically nil. 
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